WHO Drug Information Vol. 14, No. 1, 2000
(2000; 81 pages) View the PDF document
Table of Contents
Open this folder and view contentsGeneral Policy Issues
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsCurrent Topics
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsGeneral Information
Close this folderRegulatory and Safety Matters
View the documentTroglitazone withdrawn
View the documentCisapride and cardiac effects
View the documentCisapride: changes to labelling
View the documentCisapride: updated warning issued
View the documentSt John's wort: recommendations for use
View the documentNorthern hemisphere influenza vaccine
View the documentNicotine replacement therapy
View the documentAnorectic agents: suspension of marketing authorization
View the documentInsulin cartridges: leakage risk
View the documentZimox®: trade name duplication and risk of errors
View the documentBenzbromarone and hepatitis
View the documentNevirapine: severe cutaneous reactions
View the documentFDA cannot regulate tobacco industry
View the documentNew Internet website: information for consumers
View the documentCyber warnings for drug sales via the Internet
View the documentTriax®: a harmful product sold on the Internet
View the documentIllegal products on the market
View the documentEpoetin alfa: inappropriate practices compromise product sterility
View the documentPropylene glycol and amprenavir
View the documentTrastuzumab: pulmonary reactions
Open this folder and view contentsATC/DDD Classification
Open this folder and view contentsRecent Publications and Documents
Open this folder and view contentsInternational Nonproprietary Names for Pharmaceutical Substances (INN)
View the documentSelected WHO Publications of Related Interest
 

Northern hemisphere influenza vaccine

World Health Organization - The composition of the vaccine for the November 2000-April 2001 influenza season in the Northern hemisphere has been determined and communicated to vaccine manufacturers.

• an A/Moscow/10/99(H3N2)-like virus
• an A/New Caledonia/20/99(H1N1)-like virus
• a B/Beijing/184/93-like virus+

WHO strongly recommends the use of vaccine as an effective preventive measure against this potentially fatal disease. Even in those cases when the vaccine does not fully protect against the disease, severity of illness and frequency of serious complications are reduced.

Specific vaccine viruses used in each country should be approved by the national control authorities. National public health authorities are responsible for recommendations regarding use of vaccines. All WHO recommendations are published and communicated to public health authorities, national control authorities and influenza vaccine manufacturers. Updated epidemiological information is available on http://www.who.ch/emc/flu/index.htm and the geographical information system, Flunet, at http://oms.b3e.juu.fr/flunet.

Reference: Recommended composition of influenza virus vaccines for use in the 2000-2001 season. Weekly Epidemiological Record, 75: 61-65 (2000).

to previous section to next section
 

Last updated: May 3, 2013